Search - tctmd.com

Displaying 1 - 4 of 4

Sort: Relevancy | Date

Funding the Future: How Industry Support for CV Trials Could Evolve

News Features

Funding the Future: How Industry Support for CV Trials Could Evolve

Michael O'Riordan

December 17, 2020

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

News Daily News

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

May 04, 2018

Rapid Rule-Out Strategy with High-Sensitivity Troponin Shows Promise Ahead of US Commercial Availability of Test

News Daily News

Rapid Rule-Out Strategy With High-Sensitivity Troponin Shows Promise Ahead of US Commercial Availability of Test

April 17, 2017

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.